	Application No.	Applicant(s)	Applicant(s)	
Notice of Allowability	10/789,968	CONKLIN ET AL.	CONKLIN ET AL.	
	Examiner	Art Unit		
	Prema M. Mertz	1646		
The MAILING DATE of this communication appeal All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIOF of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in the or other appropriate communicement. This application is sulfaction in the communicement of the communicement	his application. If not include ication will be mailed in due o	d course. THIS	
1. \boxtimes This communication is responsive to <u>the amendment filed</u>	<u>6/21/2006</u> .			
2. The allowed claim(s) is/are <u>1-5, 27, 6, 8, 10, 12, 14, 16-26,</u>	renumbered 1-5, 6, 7, 8, 9, 10	0, 11, 12-22, respectively.		
 3. Acknowledgment is made of a claim for foreign priority ur a) All b) Some* c) None of the: 1. Certified copies of the priority documents have 2. Certified copies of the priority documents have 3. Copies of the certified copies of the priority do 	be been received. be been received in Application	No	ion from the	
International Bureau (PCT Rule 17.2(a)).				
* Certified copies not received:				
Applicant has THREE MONTHS FROM THE "MAILING DATE" noted below. Failure to timely comply will result in ABANDONN THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		reply complying with the req	uirements	
4. A SUBSTITUTE OATH OR DECLARATION must be subm INFORMAL PATENT APPLICATION (PTO-152) which give	itted. Note the attached EXANes reason(s) why the oath or d	INER'S AMENDMENT or N leclaration is deficient.	OTICE OF	
5. CORRECTED DRAWINGS (as "replacement sheets") mus	st be submitted.			
(a) 🔲 including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached				
1) 🗌 hereto or 2) 🔲 to Paper No./Mail Date	,			
(b) including changes required by the attached Examiner' Paper No./Mail Date				
Identifying indicia such as the application number (see 37 CFR 1 each sheet. Replacement sheet(s) should be labeled as such in t	.84(c)) should be written on the header according to 37 CFR	drawings in the front (not the 1.121(d).	back) of	
6. DEPOSIT OF and/or INFORMATION about the depo attached Examiner's comment regarding REQUIREMENT	SIT OF BIOLOGICAL MATER FOR THE DEPOSIT OF BIOL	RIAL must be submitted. N OGICAL MATERIAL.	lote the	
Attachment(s) 1. ☐ Notice of References Cited (PTO-892) 2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948) 3. ☑ Information Disclosure Statements (PTO-1449 or PTO/SB/0	6. ☐ Interview Sur Paper No./M	rmal Patent Application (PT0 nmary (PT0-413), lail Date mendment/Comment)-152)	
Paper No./Mail Date 2/27/04 4. Examiner's Comment Regarding Requirement for Deposit		tatement of Reasons for Allo	wance	
of Biological Material	9. Other			
		Prema MERT PRIMARY EXAM		

Application/Control Number: 10/789,968

Art Unit: 1646

The preliminary amendment submitted on 6/21/2006 and the terminal disclaimer 1.

Page 2

submitted on 6/16/2006 have been entered.

An Examiner's Amendment to the record appears below. Should the changes and/or 2.

additions be unacceptable to applicant, an amendment may be filed as provided by 37 C.F.R.

§ 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the

payment of the Issue Fee.

Authorization for this Examiner's Amendment was given in a telephone interview with

Shelby J. Walker on 6/7/2006.

3. The application has been amended as follows:

IN THE CLAIMS:

Claim 16 (currently amended) An anti-idiotypic antibody which binds to an antibody according

to any one of claims 1, 2, 6, 8, 10, 12, or 14.

In claim 17, line 1, before "antibody" insert –isolated--.

In claim 23, line 1, before "antibody" insert –isolated--.

In claim 23, line 2, delete "comprises an" insert -- consists of the--.

Application/Control Number: 10/789,968 Page 3

Art Unit: 1646

4

4. Claims 1-5, 27, 6, 8, 10, 12, 14, 16-26, are allowable and have been renumbered 1-5, 6, 7, 8, 9, 10, 11, 12-22, respectively.

- 5. The title of the invention has been amended to recite "antibody to mammalian cytokine-like polypeptide-10".
- 6. The following is an Examiner's Statement of Reasons for Allowance:

None of the prior art of record describe or suggest an antibody which binds to a polypeptide consisting of SEQ ID NO:2, and a method of producing said antibody.

7. Any comments considered necessary by applicant must be submitted no later than the payment of the Issue Fee and, to avoid processing delays, should preferably **accompany** the Issue Fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Advisory Information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Prema Mertz whose telephone number is (571) 272-0876. The examiner can normally be reached on Monday-Friday from 7:00AM to 3:30PM (Eastern time).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Nickol, can be reached on (571) 272-0835.

Official papers filed by fax should be directed to (571) 273-8300. Faxed draft or informal communications with the examiner should be directed to (571) 273-0876.

Application/Control Number: 10/789,968

Art Unit: 1646

e 0 3 ---

Information regarding the status of an application may be obtained from the Patent application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Prema Mertz Ph.D., J.D. Primary Examiner Art Unit 1646 August 3, 2006 Page 4